News
January 7, 2008 - Osiris Therapeutics Inc. has reclaimed sole worldwide rights to cardiovascular indications for Prochymal and terminated its development and commercialization agreement with Boston Scientific Corp. in order to provide Osiris with the flexibility to enter more strategically beneficial relationships.
January 06, 2008
News
January 7, 2008 – Patients with atrial flutter and atrial fibrillation may require additional sites of ablation to ...
January 06, 2008News
January 3, 2008 - A study reported in the Jan. 3 New England Journal of Medicine found that one third of patients who ...
January 03, 2008Sponsored Content
Feature | Thrombectomy Devices
Venous thromboembolism (VTE), and pulmonary embolism (PE) in particular, are among the most complex and dangerous acute ...
June 01, 2026News
January 3, 2008 – Abiomed Inc. selected Tufts-New England Medical Center (Tufts-NEMC) as a “Center of Excellence” for ...
January 02, 2008News
January 3, 2008 - A patient’s physical activity status is a significant and robust predictor of all-cause mortality in ...
January 02, 2008News
January 3, 2008 - A modular stent graft that inserts multiple, caudally-directed branches to the visceral arteries to ...
January 02, 2008Sponsored Content
Feature | Cardiac Imaging
Sponsored Content — According to the American Heart Association, cardiovascular disease is the leading cause of death in ...
March 13, 2026News
January 3, 2008 - Medical Simulation Corp. and Edwards Lifesciences Corp. will launch the Edwards SAPIEN Transcatheter ...
January 02, 2008News
January 2, 2008 – Allergic-like reactions to gadolinium-containing contrast injections in adults and pediatric patients ...
January 01, 2008News
December 28, 2007 - The data converter and amplifiers market for portable imaging systems will reach $582.7 million in ...
December 27, 2007Sponsored Content
Feature | Nuclear Imaging
Cardiac PET/CT represents a major advancement in cardiovascular diagnostics, offering significant clinical and ...
November 12, 2025News
December 29, 2007 - Boston Scientific Corp. received CE Mark approval for its LIVIAN cardiac resynchronization therapy defibrillator (CRT-D), which treats heart failure and is designed to help protect patients at risk of sudden cardiac death by monitoring heartbeats in heart failure patients and delivering small electrical impulses that may improve the heart’s pumping ability.
December 27, 2007News
December 27, 2007 - XTENT Inc. announced that it has submitted its application to the designated European Notified Body ...
December 26, 2007News
December 21, 2007 - Edwards Lifesciences Corp. (Edwards) has completed its acquisition of certain assets of the ...
December 26, 2007Sponsored Content
Feature
SPONSORED CONTENT — Studycast is a comprehensive imaging workflow system that allows healthcare professionals to work ...
June 17, 2025News
December 26, 2007 - Boston Scientific Corp. announced its TAXUS Liberte paclitaxel-eluting coronary stent system has ...
December 26, 2007Technology
Microsoft Corp. recently launched HealthVault, a software and services platform aimed at helping people better manage their health information.
December 26, 2007News
December 27, 2007 - Several new studies on genetics and stem cell research, along with studies that continue to debate the use of stents to clear coronary artery blockages are among the top research advances in heart disease and stroke for 2007, said Daniel W. Jones, M.D., president of the American Heart Association.
December 26, 2007